CoChat

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Activation of the proapoptotic receptor death receptor5 (DR5) in various cancer cells triggers programmed cell death through the extrinsic pathway. We have generated a fully human monoclonal antibody (Apomab) that induces tumor cell apoptosis through DR5 and investigated the structural features of its interaction with DR5. Biochemical studies showed that Apomab binds DR5 tightly and selectively. X-ray crystallographic analysis of the complex between the Apomab Fab fragment and the DR5 ectodomain revealed an interaction epitope that partially overlaps with both regions of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand binding site. Apomab induced DR5 clustering at the cell surface and stimulated a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Apomab's proapoptotic activity. In vitro, Apomab triggered apoptosis in cancer cells, while sparing normal hepatocytes even upon anti-Fc crosslinking. In vivo, Apomab exerted potent antitumor activity as a single agent or in combination with chemotherapy in xenograft models, including those based on colorectal, non-small cell lung and pancreatic cancer cell lines. These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.cdd.4402306

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 51 references

Cited by

See all 152

Metadata

Authors
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., & Ashkenazi, A.
Affiliations
Genentech (US)
Corresponding author
Ashkenazi, A
Venue
Cell Death & Differentiation
Published
2008-01-25
Volume
15
Issue
4
Pages
751-761
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2074106785
Cited by
148
References
51
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 1 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 7 · 2013: 19 · 2012: 12
FWCI
6.04
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cell Death and Differentiation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
DR5, agonistic monoclonal antibody, antigen-antibody reaction, extrinsic apoptotic pathway, TRAIL receptors, FADD, caspase-8, receptor clustering, selective cytotoxicity, anticancer activity, colorectal cancer, non-small cell lung cancer, pancreatic cancer
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Affinity, Antibody Specificity, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Antibody, Dose-Response Relationship, Drug, Female, Humans, Mice, Nude, Models, Molecular, Neoplasms, Experimental, Protein Binding, Protein Conformation, Receptor Aggregation, Time Factors, Signal Transduction, Apoptosis, Crystallography, X-Ray, Epitope Mapping, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Caspase 8, Fas-Associated Death Domain Protein, Receptors, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. https://app.cochat.ai/papers/10.1038/sj.cdd.4402306
The paper
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., & Ashkenazi, A. (2008). Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death & Differentiation. https://doi.org/10.1038/sj.cdd.4402306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.